A

AtriCure

Sells ablation devices for atrial fibrillation

Regional Sales Manager

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's, MBA
Wuhan, Hubei, China
In Person
Sales & Account ManagementBusiness Development & Partnerships

About the job

Requirements
  • A degree in a scientific or medical area is required.
  • At least five years of medical device sales experience is required.
  • Proficiency in Microsoft Office applications, including Word, Excel, PowerPoint, and Outlook, is required.
  • The candidate must be eligible to work in Mainland China without employer sponsorship.
  • The role requires travel an average of 50% of the time.
Responsibilities
  • Achieve or exceed quarterly and annual sub-dealer order targets.
  • Work with Master and Sub-Dealers to meet targets that reflect end-user consumption.
  • Influence the Master Distributor to manage Sub-Dealers and engage regional key opinion leaders (KOLs).
  • Initiate Sub-Dealer screening and appointments in each area with the Master Dealer.
  • Conduct bi-weekly business reviews with Sub-Dealers and joint quarterly performance reviews with Sub-Dealers and the Master Dealer.
  • Establish productive professional relationships with key personnel in assigned partner accounts.
  • Manage Sub-Dealer follow-up according to the awareness, trial, and repeat model of new account development.
  • Regularly analyze and update key account market information with Sub-Dealers.
  • Collaborate with Therapy Development, Marketing, and Professional Education teams.
  • Partner with the Country Director, Marketing Director, Therapy Development team, and KOLs to execute marketing activities in the field.
  • Work with the Country Director and Marketing and Therapy Development teams to complete segmentation, targeting, positioning, and KOL tiering, and execute KOL action plans.
  • Track and follow up on marketing and sales activity metrics and provide feedback to the China leadership team.
  • Collaborate with Therapy Development, T&E teams, and healthcare professionals to address healthcare professional training and education needs and resolve issues to support consistent clinical outcomes.
  • Work with the Therapy Development team to provide Round Table Meetings in target accounts.
  • Collect monthly business intelligence on accounts from channel partners.
  • Collect and manage competitor intelligence from market information.
Desired Qualifications
  • An MBA or other graduate degree is preferred.
  • Seven years of medical device sales experience is preferred.
  • Previous people management experience is preferred.
  • A track record of developing new therapies in China is preferred.

About the company

AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mason, Ohio

Founded

1994

Get referred to AtriCure

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $153.6 million, and management raised full-year guidance.
  • BoxX-NoAF enrollment surpassed 500 patients in July 2026, ahead of schedule.
  • cryoXT launched in 2025 and should contribute more meaningfully in late 2026.

What critics are saying

  • MIS ablation faces pulsed-field ablation cannibalization; Q1 2026 revenue there fell 25%.
  • Gross margin dips below 77% in Q3 2026 as the new plant ramps.
  • If BoxX-NoAF or LeAAPS miss, AtriCure loses its 2030 $1 billion thesis.

What makes AtriCure unique

  • AtriCure owns a surgical AFib niche spanning ablation, appendage management, and cryoanalgesia.
  • cryoSPHERE MAX and EnCompass drove Q2 2026 growth, highlighting surgeon adoption.
  • BoxX-NoAF and LeAAPS create label-expansion optionality unavailable to catheter ablation rivals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Wellness Program

401(k) Company Match

Parental Leave

Pet Insurance

Employee Stock Purchase Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 13th, 2026
AtriCure CTO sells $200K in shares, retains $7.9M stake

AtriCure's Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on 8 September 2026 at $55 per share, according to an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan established in February 2026. Privitera retains approximately 147,000 shares in the medical device company, valued at $7.9 million based on the 8 September closing price of $53.73. The stock has risen 49% over the preceding 12 months. AtriCure, which makes specialised devices for cardiac tissue treatment, reported trailing twelve-month revenue of $569.6 million and net income of $10.6 million. The company has a market capitalisation of $2.7 billion.

Yahoo Finance
Aug 12th, 2026
AtriCure targets $1B revenue by 2030 as pain management volumes jump 25%

AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.

Yahoo Finance
Jul 28th, 2026
AtriCure beats Q2 estimates with $153.6M revenue and 800% EPS surprise, raises full-year guidance

AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.

Yahoo Finance
Jul 24th, 2026
AtriCure reports $154M revenue, 13% growth and $9M net income in Q2 2026

AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.

Yahoo Finance
Jun 4th, 2026
AtriCure accelerates heart disease trial by 12 months, beats Q1 revenue by $2M

AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.